Jean Jacques Bienaime Purchases 2,000 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime acquired 2,000 shares of Immunome stock in a transaction on Tuesday, May 21st. The shares were bought at an average cost of $13.57 per share, with a total value of $27,140.00. Following the completion of the purchase, the director now owns 9,615 shares in the company, valued at $130,475.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Immunome Stock Down 0.6 %

Shares of NASDAQ IMNM opened at $14.34 on Friday. Immunome, Inc. has a 12-month low of $4.50 and a 12-month high of $30.96. The firm’s 50-day moving average is $18.27 and its two-hundred day moving average is $15.91.

Immunome (NASDAQ:IMNM) last announced its earnings results on Thursday, March 28th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.26). Immunome had a negative net margin of 1,829.44% and a negative return on equity of 37.33%. The firm had revenue of $3.83 million during the quarter, compared to analyst estimates of $3.40 million. As a group, equities analysts predict that Immunome, Inc. will post -1.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunome

Several institutional investors and hedge funds have recently modified their holdings of IMNM. Dorsey Wright & Associates acquired a new stake in shares of Immunome during the third quarter worth $26,000. EntryPoint Capital LLC increased its position in Immunome by 21,864.0% during the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after purchasing an additional 5,466 shares during the last quarter. Jump Financial LLC acquired a new position in shares of Immunome in the 4th quarter valued at $172,000. Sei Investments Co. purchased a new stake in shares of Immunome during the 1st quarter valued at $469,000. Finally, Clear Creek Financial Management LLC purchased a new position in shares of Immunome in the 1st quarter worth $547,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

IMNM has been the subject of several analyst reports. Guggenheim assumed coverage on Immunome in a research note on Monday, April 15th. They set a “buy” rating and a $35.00 price target for the company. JPMorgan Chase & Co. started coverage on shares of Immunome in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price for the company. SVB Leerink began coverage on shares of Immunome in a report on Monday, January 29th. They issued an “outperform” rating and a $30.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Immunome in a report on Tuesday, May 14th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of Immunome in a report on Monday, January 29th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $30.50.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.